US 12,280,063 B2
Anti-retroviral therapies and reverse transcriptase inhibitors for treatment of Alzheimer's disease
Jerold Chun, La Jolla, CA (US); William J. Romanow, La Jolla, CA (US); Ming-Hsiang Lee, La Jolla, CA (US); and Victoria Blaho, La Jolla, CA (US)
Assigned to SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, La Jolla, CA (US)
Appl. No. 17/253,781
Filed by Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (US)
PCT Filed Jun. 20, 2019, PCT No. PCT/US2019/038284
§ 371(c)(1), (2) Date Dec. 18, 2020,
PCT Pub. No. WO2019/246422, PCT Pub. Date Dec. 26, 2019.
Claims priority of provisional application 62/687,428, filed on Jun. 20, 2018.
Prior Publication US 2021/0267995 A1, Sep. 2, 2021
Int. Cl. A61K 31/551 (2006.01); A61K 31/13 (2006.01); A61K 31/27 (2006.01); A61K 31/445 (2006.01); A61K 31/496 (2006.01); A61K 31/505 (2006.01); A61K 31/513 (2006.01); A61K 31/538 (2006.01); A61K 31/55 (2006.01); A61K 31/7072 (2006.01); A61K 45/06 (2006.01); A61P 25/28 (2006.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01)
CPC A61K 31/551 (2013.01) [A61K 31/13 (2013.01); A61K 31/27 (2013.01); A61K 31/445 (2013.01); A61K 31/496 (2013.01); A61K 31/505 (2013.01); A61K 31/513 (2013.01); A61K 31/538 (2013.01); A61K 31/55 (2013.01); A61K 31/7072 (2013.01); A61K 45/06 (2013.01); A61P 25/28 (2018.01); C12Q 1/6883 (2013.01); G01N 33/6896 (2013.01); G01N 2800/2821 (2013.01)] 17 Claims
 
1. A method of inhibiting generation of one or more non-classical variants of an amyloid precursor protein (APP) gene in an individual in need thereof, the method comprising: administering to the individual a nucleoside reverse transcriptase inhibitor or a salt thereof, wherein the individual is a human and has one or more non-classical variants of an amyloid precursor protein (APP) gene; wherein the one or more non-classical variants comprise a portion or all of exon 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or any combination thereof of the APP gene, thereby inhibiting generation of the one or more non-classical variants of the APP gene in the individual; and
wherein the nucleoside reverse transcriptase inhibitor is selected from the group consisting of azidothymidine and abacavir.